SLDB - Solid Biosciences Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
35.63
+3.21 (+9.90%)
As of 3:23PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close32.42
Open32.49
Bid34.45 x 900
Ask34.66 x 1000
Day's Range31.29 - 35.63
52 Week Range6.83 - 54.84
Volume82,613
Avg. Volume213,893
Market Cap1.262B
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.52
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est44.60
Trade prices are not sourced from all markets
  • GlobeNewswire11 days ago

    Solid Biosciences to Present at the Chardan Genetic Medicines Conference

    CAMBRIDGE, Mass., Oct. 05, 2018 -- Solid Biosciences Inc. (NASDAQ: SLDB) today announced that management will participate in a question and answer format presentation at the.

  • GlobeNewswire15 days ago

    Solid Biosciences to Present at the Cell & Gene Meeting on the Mesa

    CAMBRIDGE, Mass., Oct. 01, 2018-- Solid Biosciences Inc. today announced that management will present at the Cell & Gene Meeting on the Mesa on Wednesday, October 3, 2018 at 3:30 pm PT in La Jolla, California.. ...

  • Solid Biosciences and Its Focus on Duchenne Muscular Dystrophy
    Market Realistlast month

    Solid Biosciences and Its Focus on Duchenne Muscular Dystrophy

    Solid Biosciences (SLDB) is focused on developing products that treat Duchenne muscular dystrophy (or DMD), a genetic muscle-wasting disease caused by mutations in the dystrophin gene. Solid Biosciences’ SGT-001 is being developed to restore functional dystrophin protein expression in patients’ muscles. The drug has received rare pediatric disease designation in the United States and orphan drug designation in the United States and the European Union.

  • What Solid Biosciences’ Valuation Trend Indicates
    Market Realistlast month

    What Solid Biosciences’ Valuation Trend Indicates

    Solid Biosciences (SLDB) incurred a net loss of $17.98 million in the second quarter of 2018, which compares to a net loss of $11.31 million in the second quarter of 2017, translating to a net loss per share of $0.52 in the second quarter of 2018. Its net loss per share was $0.66 in the second quarter of 2017. The decrease in net loss per share was due to an increase in the company’s outstanding shares, which increased from 17.04 million in the second quarter of 2017 to 34.45 million in the second quarter of 2018.

  • BioMarin Pharmaceutical and Its Promising Research Pipeline
    Market Realistlast month

    BioMarin Pharmaceutical and Its Promising Research Pipeline

    Stocks focused on gene therapy have garnered strong investor interest in 2018. While some of them have been climbing steadily, others have received strong price corrections on pipeline news. In this series, we’ll analyze four companies: BioMarin Pharmaceutical (BMRN), Solid Biosciences (SLDB), Spark Therapeutics (ONCE), and uniQure (QURE).

  • GlobeNewswirelast month

    Solid Biosciences Welcomes Sukumar Nagendran, M.D., To Its Board Of Directors

    Solid Biosciences Inc. (SLDB) today announced that Sukumar Nagendran, M.D., has been elected to its Board of Directors. Dr. Nagendran brings to Solid more than 30 years of experience in key functional areas, including gene therapy development, clinical strategy, medical affairs and diagnostics. “Dr. Nagendran is an accomplished physician, drug developer and biotech executive, with deep and relevant experience in gene therapy development and proven results,” said Ilan Ganot, Chief Executive Officer, Co-Founder and President of Solid Biosciences.

  • Benzingalast month

    Credit Suisse Joins Consensus To Prescribe Sarepta

    The Street has a lot of faith in Sarepta Therapeutics, Inc. (NASDAQ: SRPT ). The biotech firm notched its 20th bullish rating Thursday to further neutralize a lone Hold. The Rating Credit Suisse analysts ...

  • MarketWatch2 months ago

    Scholar Rock stock tumbles 11% as Pfizer discontinues similar medication

    Scholar Rock Holding Corp. (srrk) shares dropped 11% in active Thursday trade after Pfizer Inc. (pfe) announced it plans to stop two ongoing clinical trials for a similar rare-disease drug. "Although SRRK has not formally announced its strategy in DMD, we see the setting as ideal for lead candidate SRK-015, which could complement the gene therapies that are in development from Sarepta (srpt) Solid Bio (sldb) and Pfizer...Neither SRPT and SLDB have anti-myostatin programs of their own," he said, adding that SRK-015 "should be more selective and provide an improved therapeutic window relative to programs like doma which target mature myostatin." Phase 1 safety data for the therapy could be available before the end of the year, providing a catalyst for Scholar Rock shares, according to Nierengarten.

  • GlobeNewswire2 months ago

    Solid Biosciences Reports Second Quarter 2018 Financial Results and Provides Business Update

    -IGNITE DMD Phase I/II Clinical Trial Patient Screening Has Resumed-. CAMBRIDGE, Mass., Aug. 10, 2018-- Solid Biosciences Inc. today reported financial results for the second quarter ended June 30, 2018 ...

  • Benzinga2 months ago

    Morgan Stanley Buys Into Sarepta Amid Sell-Off, Sees $600M Recurring Opportunity In DMD Candidate

    A manufacturing-related hold on Sarepta Therapeutics Inc (NASDAQ: SRPT )’s Duchenne muscular dystrophy candidate catalyzed a recent sell-off. Morgan Stanley sees a buying opportunity in the otherwise-lauded ...

  • Benzinga3 months ago

    Sarepta's Clinical Hold Could Be A Solid Biosciences Catalyst, Says Bullish Chardan Analyst

    Sarepta Therapeutics Inc (NASDAQ: SRPT ) announced a manufacturing-related hold Wednesday on its Phase 1/2 trial of microdystrophin gene therapy for Duchenne muscular dystrophy. Solid Biosciences Inc (NASDAQ: ...

  • Why resTORbio Stock Is Seeing Solid Growth Today
    Market Realist3 months ago

    Why resTORbio Stock Is Seeing Solid Growth Today

    Today, resTORbio (TORC) is trading at $13.36, which represents ~48.28% growth compared to yesterday. On July 24, resTORbio stock closed at $9.01, which represents ~19% growth from its 52-week low of $7.54 on April 10. TORC hit its 52-week high of $21.09 on February 26. Today, resTORbio announced positive results from its Phase 2b trial of RTB101 to evaluate the safety and efficacy of the drug in older individuals who are at high risk of morbidity and mortality due to respiratory tract infections.

  • Benzinga3 months ago

    A Look At IPOs So Far In 2018

    The first half of 2018 brought Dropbox Inc (NASDAQ: DBX ), Spotify Technology SA (NYSE: SPOT ) and 118 other market newbies raising an aggregate $35.2 billion — the most since 2014. Bettors on the young ...

  • 3 Best Gene Therapy Stocks of 2018 (So Far)
    Motley Fool3 months ago

    3 Best Gene Therapy Stocks of 2018 (So Far)

    These gene therapy stocks have generated huge returns so far this year. But can they keep up their winning ways?

  • Benzinga4 months ago

    Analyst: Solid Biosciences A Solid Buy On Sarepta's Progress

    The Street grew more bullish on Solid Biosciences Inc (NASDAQ: SLDB ) last week following progress announcements on Solid and peer candidates. At least three analysts raised their valuation targets: The ...

  • Are These 3 Red-Hot Gene Therapy Stocks Still Buys?
    Motley Fool4 months ago

    Are These 3 Red-Hot Gene Therapy Stocks Still Buys?

    Is continued success in the cards for these biotech stocks?

  • 3 Biotech Stocks That Soared This Week: Are They Buys?
    Motley Fool4 months ago

    3 Biotech Stocks That Soared This Week: Are They Buys?

    Can these sizzling biotech stocks stay hot?

  • DMD Research Veers Toward Gene Therapy: 3 Stocks in Focus
    Zacks4 months ago

    DMD Research Veers Toward Gene Therapy: 3 Stocks in Focus

    Investor focus is on the DMD segment this week with Sarepta presenting encouraging gene therapy study data and the FDA lifting its clinical hold on Solid Biosciences' gene therapy study.

  • This Biotech Is Cratering On Sarepta's Success — But Could Be 'Superior'
    Investor's Business Daily4 months ago

    This Biotech Is Cratering On Sarepta's Success — But Could Be 'Superior'

    Solid Biosciences plunged Wednesday on high volume after rival Sarepta Therapeutics reported strong data for its Duchenne muscular dystrophy treatment.

  • Solid Biosciences’ Stock Price Rose 46.6% on June 19
    Market Realist4 months ago

    Solid Biosciences’ Stock Price Rose 46.6% on June 19

    On June 19, Solid Biosciences’ (SLDB) stock price rose ~46.6% to $43.00. On June 19, Solid Biosciences’ stock price hit a 52-week high of $54.84.

  • Biotech Stock Roundup: SRPT & SLDB Soar on Positive Data, ANIK & ZIOP Crash
    Zacks4 months ago

    Biotech Stock Roundup: SRPT & SLDB Soar on Positive Data, ANIK & ZIOP Crash

    The biotech sector showed volatility with a few companies gaining on positive data readouts while a few plunging on dismal results.

  • ACCESSWIRE4 months ago

    Today’s Research Reports on Stocks to Watch: Foundation Medicine and Solid Biosciences

    NEW YORK, NY / ACCESSWIRE / June 20, 2018 / Shares of Foundation Medicine exploded on Tuesday after announcing that it has entered into a definitive merger agreement for Roche to acquire the outstanding shares of FMI`s common stock not already owned by Roche and its affiliates at a price of US$ 137.00 per share. Shares of Solid Biosciences also broke out after announcing that the FDA has lifted a clinical hold on the company's phase I/II trial, IGNITE DMD, for its experimental candidate, SGT-001. Foundation Medicine, Inc. shares closed up 28.46% on Tuesday, with about 6.3 million shares traded compared to an average trading volume of about 409,00 shares.

  • Why CVS Health, Foundation Medicine, and Solid Biosciences Jumped Today
    Motley Fool4 months ago

    Why CVS Health, Foundation Medicine, and Solid Biosciences Jumped Today

    Find out why healthcare made a big leap in today's market action.